Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

705
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
705
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

319
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
319
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

391
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
391
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

477
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
477
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

393
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
393
Mitral Regurgitation IV: Nursing Management01:28

Mitral Regurgitation IV: Nursing Management

383
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
383

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intra-pericardial thrombin injection as bailout strategy in iatrogenic pericardial tamponade.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2022
Same author

Interdisciplinary consensus on indications for transfemoral transcatheter aortic valve implantation (TF-TAVI) : Joint Consensus Document of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte e.V. (ALKK) and cooperating Cardiac Surgery Departments.

Clinical research in cardiology : official journal of the German Cardiac Society·2019
Same author

[Acute coronary syndrome with ST-elevation].

Herz·2019
Same author

The German CPU registry: Comparison of smokers and nonsmokers.

Herz·2018
Same author

EAPCI focus on the WEAPCI survey on radiation exposure and regulations in European catheterisation laboratories Julinda Mehilli, Chairwoman.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2016
Same author

[Interventional treatment in acute coronary syndrome].

Deutsche medizinische Wochenschrift (1946)·2014

Related Experiment Video

Updated: Feb 17, 2026

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
08:31

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

Published on: October 16, 2021

4.5K

[Management of valvular heart disease : ESC/EACTS guidelines 2017].

M Haude1

  • 1Medizinische Klinik I, Städtische Kliniken Neuss, Lukaskrankenhaus GmbH, Preußenstr. 84, 41464, Neuss, Deutschland. mhaude@lukasneuss.de.

Herz
|December 1, 2017
PubMed
Summary

The European Society of Cardiology updated guidelines for valvular heart disease management. Transcatheter aortic valve implantation (TAVI) is now recommended for more patients, while catheter therapies for other valve diseases need more data.

Keywords:
Antithrombotic therapyHeart teamHeart valve centers of excellenceHeart valvesTranscatheter aortic valve replacement

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K
Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
08:12

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels

Published on: May 26, 2023

2.5K

Related Experiment Videos

Last Updated: Feb 17, 2026

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
08:31

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

Published on: October 16, 2021

4.5K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K
Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
08:12

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels

Published on: May 26, 2023

2.5K

Area of Science:

  • Cardiology
  • Cardiovascular Surgery

Background:

  • The European Society of Cardiology and European Association for Cardio-Thoracic Surgery have released updated guidelines for valvular heart disease management.
  • Recent randomized trials have influenced recommendations for aortic valve stenosis treatment.

Purpose of the Study:

  • To provide updated recommendations for the diagnosis and treatment of valvular heart diseases.
  • To address the role of catheter-based therapies and antithrombotic strategies.
  • To emphasize the importance of multidisciplinary heart teams and specialized centers.

Main Methods:

  • Review and synthesis of recent randomized trial data.
  • Development of updated clinical recommendations based on evidence.
  • Focus on specific valvular conditions like aortic stenosis, mitral, and tricuspid disease.

Main Results:

  • Transcatheter aortic valve implantation (TAVI) recommendations expanded to include patients at lower surgical risk.
  • Catheter-based therapies for mitral and tricuspid valve disease have less robust recommendations due to limited data.
  • Updated guidance on concomitant antithrombotic therapy in valvular heart disease, coronary artery disease, and arrhythmias.

Conclusions:

  • The updated guidelines reflect advancements in transcatheter aortic valve implantation.
  • Further research is needed to strengthen recommendations for catheter-based therapies in mitral and tricuspid valve disease.
  • Establishment of heart valve centers of excellence is proposed to ensure high-quality patient care.